<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00688961</url>
  </required_header>
  <id_info>
    <org_study_id>WSH-001</org_study_id>
    <nct_id>NCT00688961</nct_id>
  </id_info>
  <brief_title>Effects of Omacor and Aspirin on Platelet Function</brief_title>
  <official_title>A Pilot Study of the Effects of Omacor (Alone and With Aspirin) on Platelet Function in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanford Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanford Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Omacor (now Lovaza) is a pharmaceutical omega-3 fatty acid product. Omega-3 fatty acids can&#xD;
      affect blood clotting by altering the function of the blood platelets. Aspirin can do the&#xD;
      same. The purpose of this study is to determine the individual and combined effects of these&#xD;
      two agents on platelet function using a whole blood method.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overview&#xD;
&#xD;
      This study will explore the effects of 4 g/d of Omacor in healthy volunteers both with and&#xD;
      without concomitant aspirin therapy. The study will utilize three different analytical&#xD;
      approaches to assess platelet activation and function.&#xD;
&#xD;
      Objective&#xD;
&#xD;
      The purpose of this exploratory study is to gather preliminary information on the effects of&#xD;
      Omacor on a platelet function in healthy volunteers, both with and without concomitant&#xD;
      aspirin therapy, in order to lay the groundwork for future studies in cardiac patients taking&#xD;
      Omacor in combination with aspirin and clopidogrel.&#xD;
&#xD;
      Background/Significance&#xD;
&#xD;
      Omacor (omega-3 fatty acid ethyl esters) is approved for treatment of severe&#xD;
      hypertriglyceridemia, and may soon be approved for the treatment of moderate&#xD;
      hypertriglyceridemia in combination with statins. In other words, the use of Omacor will&#xD;
      continue to expand. The package insert notes that physicians should be attuned to the&#xD;
      possibility of increased bleeding tendencies with high dose (4 g/d) Omacor use despite the&#xD;
      fact that clinically significant bleeding has virtually never been reported with this dose&#xD;
      (or even up to 7 g of EPA+DHA) in studies in patients on concomitant anti-platelet therapy&#xD;
      undergoing highly invasive vascular procedures (e.g., diagnostic catheterization,&#xD;
      angioplasty, coronary artery bypass grafting). Nevertheless, because omega-3 fatty acids are&#xD;
      known to inhibit platelet function and to increase bleeding times(1), it is prudent to&#xD;
      explore and carefully define the effects of this dose of Omacor on platelet composition and&#xD;
      function.&#xD;
&#xD;
      Primary and Secondary Endpoints&#xD;
&#xD;
      The primary endpoint will be the effects of Omacor Â± aspirin on platelet aggregation measured&#xD;
      by whole blood impedence aggregometry in Harris's laboratory.&#xD;
&#xD;
      The secondary aims are to explore some of the molecular mechanisms by which omega-3 fatty&#xD;
      acids and/or aspirin may alter platelet function. These include spreading assays, and tests&#xD;
      of calcium and ATP release (described below). Even if the whole blood aggregation assays are&#xD;
      not altered by Omacor treatment (they will be altered by aspirin treatment), these tests are&#xD;
      sensitive to more subtle alterations in platelet function that could be missed in platelet&#xD;
      aggregation assays. Alternatively, omega-3 FAs could impact two independent pathways in&#xD;
      opposite directions, resulting in a cancelling out of the overall effect on platelet&#xD;
      aggregation. These more focused experiments will be conducted at Dr. Mark Larson's laboratory&#xD;
      at Augustana College.&#xD;
&#xD;
      Experimental Design and Methodology&#xD;
&#xD;
      Design This will be an open-label, pre- and post, 4-week trial. Blood will be drawn on day 1&#xD;
      (baseline), day 2 (1 day after taking 650 mg of aspirin), day 29 (after taking Omacor for 28&#xD;
      days), and day 30 (Omacor + 650 mg of aspirin). Platelet aggregation will be tested in each&#xD;
      blood sample.&#xD;
&#xD;
      Subjects Ten healthy volunteers will be recruited from among the staff of Sanford&#xD;
      Research/USD, Sanford School of Medicine, and Sanford Hospital; patients, students, visitors,&#xD;
      and subordinates of the investigators will not be eligible. Subjects may be male or female&#xD;
      and between the ages of 21 and 60, non-smokers, and taking no medications, vitamin pills,&#xD;
      nutritional supplements or herbal preparations. Subjects may not have a history of allergic&#xD;
      reactions to aspirin, fish or fish oils. Birth control pills are not allowed. Subject cannot&#xD;
      have an allergy to aspirin or to non-steroidal anti-inflammatory drug (NSAID) such as&#xD;
      ibuprofen (Motrin, Advil, others), naproxen (Aleve, Naprosyn, Anaprox, others), indomethacin&#xD;
      (Indocin), or ketoprofen (Orudis KT, Orudis, Oruvail), nabumetone (Relafen), oxaprozin&#xD;
      (Daypro), or tartrazine. Other exclusions include: drinking more than three alcoholic&#xD;
      beverages a day, or having any of the following conditions: an ulcer or bleeding in the&#xD;
      stomach, liver or kidney disease, bleeding or blood clotting disorder (e.g., hemophilia),&#xD;
      congestive heart failure, fluid retention, heart disease, high blood pressure, gout, asthma,&#xD;
      arthritis, or nasal polyps.&#xD;
&#xD;
      Laboratory Methods Blood will be drawn into sodium citrate for all tests. Three agonists will&#xD;
      be used in the whole blood aggregometry tests: thrombin, collagen and ADP(3). The output of&#xD;
      this instrument (Chronolog Whole Blood Aggregometer, model 504) is in ohms, with higher&#xD;
      impedance values indicating greater platelet aggregation. Because this test is conducted in&#xD;
      whole blood (i.e., erythrocytes present), it is thought to be the most&#xD;
      physiologically-relevant method for testing platelet function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Whole blood aggregometry in response to 4 agonists</measure>
    <time_frame>Day 1, 2, 29, and 30</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin (1 day after a single, 625 mg dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omacor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omacor plus aspirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>generic aspirin</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omega-3 acid ethyl esters</intervention_name>
    <description>4, 1 g capsules q.d.</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>Omacor</other_name>
    <other_name>Lovaza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects may be male or female and between the ages of 21 and 60,&#xD;
&#xD;
          -  Non-smokers,&#xD;
&#xD;
          -  Taking no medications, vitamin pills, nutritional supplements or herbal preparations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects may not have a history of allergic reactions to aspirin, fish or fish oils.&#xD;
&#xD;
          -  Birth control pills are not allowed.&#xD;
&#xD;
          -  Subject cannot have an allergy to aspirin or to non-steroidal anti-inflammatory drug&#xD;
             (NSAID) such as ibuprofen (Motrin, Advil, others), naproxen (Aleve, Naprosyn, Anaprox,&#xD;
             others), indomethacin (Indocin), or ketoprofen (Orudis KT, Orudis, Oruvail),&#xD;
             nabumetone (Relafen), oxaprozin (Daypro), or tartrazine.&#xD;
&#xD;
          -  Drinking more than three alcoholic beverages a day&#xD;
&#xD;
          -  Having any of the following conditions:&#xD;
&#xD;
               -  an ulcer or bleeding in the stomach,&#xD;
&#xD;
               -  liver or kidney disease,&#xD;
&#xD;
               -  bleeding or blood clotting disorder (e.g., hemophilia),&#xD;
&#xD;
               -  congestive heart failure,&#xD;
&#xD;
               -  fluid retention,&#xD;
&#xD;
               -  heart disease,&#xD;
&#xD;
               -  high blood pressure,&#xD;
&#xD;
               -  gout,&#xD;
&#xD;
               -  asthma,&#xD;
&#xD;
               -  arthritis, or&#xD;
&#xD;
               -  nasal polyps.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sanford Research/USD</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>May 30, 2008</study_first_submitted>
  <study_first_submitted_qc>June 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <last_update_submitted>June 2, 2008</last_update_submitted>
  <last_update_submitted_qc>June 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>William S. Harris</name_title>
    <organization>Sanford Research/USD</organization>
  </responsible_party>
  <keyword>omega-3 fatty acids</keyword>
  <keyword>aspirin</keyword>
  <keyword>platelet aggregation</keyword>
  <keyword>Healthy volunteers; no disease</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 23, 2021</submitted>
    <returned>October 19, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

